Suppr超能文献

在小鼠 MRONJ 发展过程中的巨噬细胞极化。

Macrophage Polarization during MRONJ Development in Mice.

机构信息

Private practice, Kennewick, WA, USA.

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

出版信息

J Dent Res. 2024 Aug;103(9):899-907. doi: 10.1177/00220345241258990. Epub 2024 Aug 5.

Abstract

Macrophages are important regulators of bone remodeling, and M1 polarization is observed in the setting of medication-related osteonecrosis of the jaws (MRONJ). Here, we characterize the phenotype of macrophages during early stages of MRONJ development in zoledronate (ZA)-treated mice with periodontal disease and explore the role of rosiglitazone, a drug that has been reported to lower the M1/M2 macrophage ratio, in MRONJ burden. Mice received ZA, and experimental periodontal disease (EPD) was induced around their second left maxillary molar. The mice were euthanized 1, 2, or 4 wk later. Micro-computed tomography and histologic and immunohistochemical analyses were carried out. In a separate experiment, mice were treated with ZA in the absence or presence of rosiglitazone, EPD was induced for 5 wk, and the MRONJ burden was assessed. An M1 predilection was noted in ZA versus vehicle (Veh) mice at 1, 2, or 4 wk after ligature placement. M1 cells were found to be positive for MMP-13, and their presence coincided with disruption of the surrounding collagen network in ZA mice. Rosiglitazone caused a reversal in the M1/M2 polarization in Veh and ZA mice. Rosiglitazone did not cause significant radiographic changes 5 wk after EPD in Veh or ZA animals. Importantly, percentage osteonecrosis and bone exposure were decreased in the rosiglitazone-treated versus nontreated ZA sites 5 wk after EPD. Our data point to an important role of M1 macrophage polarization with an overexpression of MMP-13 in the early phases of MRONJ development and provide insight into the use of interventional approaches promoting an M2 phenotype as a preventative means to alleviate MRONJ burden.

摘要

巨噬细胞是骨重塑的重要调节者,在药物相关性下颌骨坏死(MRONJ)中观察到 M1 极化。在这里,我们在接受唑来膦酸盐(ZA)治疗且患有牙周病的小鼠中描述了 MRONJ 发展早期阶段的巨噬细胞表型,并探讨了罗格列酮(一种已被报道降低 M1/M2 巨噬细胞比值的药物)在 MRONJ 负担中的作用。 小鼠接受 ZA 治疗,并在其第二左上颌磨牙周围诱导实验性牙周病(EPD)。 1、2 或 4 周后处死小鼠。进行了微计算机断层扫描和组织学及免疫组织化学分析。在另一个实验中,小鼠在没有或存在罗格列酮的情况下接受 ZA 治疗,诱导 EPD 5 周,并评估 MRONJ 负担。与载体(Veh)小鼠相比,在结扎后 1、2 或 4 周,ZA 小鼠中观察到 M1 偏倚。发现 M1 细胞对 MMP-13 呈阳性,并且它们的存在与 ZA 小鼠周围胶原网络的破坏相一致。罗格列酮导致 Veh 和 ZA 小鼠中的 M1/M2 极化逆转。在 Veh 或 ZA 动物中,EPD 5 周后罗格列酮并未引起明显的放射影像学变化。重要的是,EPD 5 周后,在罗格列酮治疗的 ZA 部位与未治疗的 ZA 部位相比,骨坏死百分比和骨暴露减少。我们的数据表明,M1 巨噬细胞极化及其 MMP-13 的过度表达在 MRONJ 发展的早期阶段起着重要作用,并为使用促进 M2 表型的干预方法作为减轻 MRONJ 负担的预防手段提供了见解。

相似文献

1
Macrophage Polarization during MRONJ Development in Mice.在小鼠 MRONJ 发展过程中的巨噬细胞极化。
J Dent Res. 2024 Aug;103(9):899-907. doi: 10.1177/00220345241258990. Epub 2024 Aug 5.
2
Interventions for managing medication-related osteonecrosis of the jaw.颌骨药物相关性骨坏死的管理干预措施。
Cochrane Database Syst Rev. 2017 Oct 6;10(10):CD012432. doi: 10.1002/14651858.CD012432.pub2.
3
Interventions for managing medication-related osteonecrosis of the jaw.干预措施管理与药物相关的颌骨坏死。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD012432. doi: 10.1002/14651858.CD012432.pub3.
5
Bisphosphonates in multiple myeloma: a network meta-analysis.双膦酸盐类药物治疗多发性骨髓瘤:一项网状Meta分析
Cochrane Database Syst Rev. 2012 May 16(5):CD003188. doi: 10.1002/14651858.CD003188.pub3.

本文引用的文献

6
Inflammation, Bone Healing and Osteonecrosis: From Bedside to Bench.炎症、骨愈合与骨坏死:从床边到实验室
J Inflamm Res. 2020 Nov 13;13:913-923. doi: 10.2147/JIR.S281941. eCollection 2020.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验